Literature DB >> 15160755

Specificity of SPIO particles for characterization of liver hemangiomas using MRI.

X Montet1, F Lazeyras, N Howarth, G Mentha, L Rubbia-Brandt, C D Becker, J P Vallee, F Terrier.   

Abstract

We investigated the specificity of superparamagnetic iron oxide (SPIO)-enhanced T1-weighted spin-echo (SE) magnetic resonance (MR) images for the characterization of liver hemangiomas. When imaging liver hemangiomas, which are the most frequent benign liver tumors, a method with very high specificity is required, which will obviate other studies, follow-up, or invasive diagnostic procedures such as percutaneous biopsy. Eighty-three lesions were examined by MR imaging at 1.5 T before and after intravenous injection of SPIO particles. Lesions were categorized as follows according to the final diagnosis: 37 hemangiomas, nine focal nodular hyperplasias (FNHs), 19 hepatocellular carcinomas (HCCs), and 18 metastases. Their signal intensity values were normalized to muscle and compared. The only lesions showing a significant increase in signal intensity ratio (lesion to muscle) on postcontrast T1-weighted SE images were hemangiomas (p < 0.001). The signal intensity ratio of hemangiomas increased on average by 70%. Based on receiver operating characteristic analysis and using a cutoff level of 50% signal increase, the specificity and sensitivity of SPIO-enhanced MR imaging for the characterization of hemangiomas would be 100% and 70%, respectively. The T1 effect of SPIO particles can help differentiate hemangiomas from other focal liver lesions such as FNHs, HCCs, and metastases and may obviate biopsy. When using SPIO particles for liver imaging, it is useful to add a T1-weighted sequence to T2-weighted images, thereby providing additional information for lesion characterization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15160755     DOI: 10.1007/s00261-003-0092-0

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  6 in total

Review 1.  Safety of MR liver specific contrast media.

Authors:  Marie-France Bellin; Judith A W Webb; Aart J Van Der Molen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

Review 2.  [Benign focal hepatic lesions].

Authors:  S Baroud; N Bastati; H Prosch; W Schima; A Ba-Ssalamah
Journal:  Radiologe       Date:  2011-08       Impact factor: 0.635

Review 3.  Liver haemangioma: common and uncommon findings and how to improve the differential diagnosis.

Authors:  Filipe Caseiro-Alves; Jorge Brito; Antonio Eiras Araujo; Pedro Belo-Soares; Henrique Rodrigues; Augusta Cipriano; Daniel Sousa; Didier Mathieu
Journal:  Eur Radiol       Date:  2007-01-27       Impact factor: 5.315

4.  [Modern diagnostics of cystic liver lesions and hemangiomas].

Authors:  S Pötter-Lang; G Brancatelli; N Bastati-Huber; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-01       Impact factor: 0.635

Review 5.  Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.

Authors:  Ahmed Ba-Ssalamah; Martin Uffmann; Sanjai Saini; Nina Bastati; Christian Herold; Wolfgang Schima
Journal:  Eur Radiol       Date:  2008-09-23       Impact factor: 5.315

6.  MRI after magnetic drug targeting in patients with advanced solid malignant tumors.

Authors:  A-J Lemke; M-I Senfft von Pilsach; A Lübbe; C Bergemann; H Riess; R Felix
Journal:  Eur Radiol       Date:  2004-08-05       Impact factor: 5.315

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.